Effects of Platelet-Rich Plasma Therapy on Ovarian Reserve in Women with Premature Ovarian Insufficiency: A Systematic Review

Yogi Wibowo Parhusip, Dian Tjahyadi, Gatot Nyarumenteng Adhipurnawan Winarno


Abstract


Introduction: Premature ovarian insufficiency (POI) is characterized by loss of ovarian function before age 40, resulting in elevated gonadotropins, reduced anti-Müllerian hormone (AMH), and limited fertility options. This systematic review evaluated the effects of platelet-rich plasma (PRP), secretome, and stem cell therapies on ovarian reserve restoration.
Methods: Following PRISMA 2020 guidelines, PubMed, Cochrane, and MEDLINE were searched for human clinical studies published from 2020–2025. Prospective and retrospective studies involving women with POI receiving PRP, secretome, or stem cell interventions were included. Methodological quality was assessed using JBI Critical Appraisal Checklists.
Results: Five studies involving 211 participants were analyzed. PRP showed a 100% reported success rate, with antral follicle count increases of 75 – 176%, AMH increases of 47 – 369%, and FSH reductions of 16 – 62%. Menstruation resumed in 60% of patients. Stem cell therapy showed a 50% overall success rate, while secretome therapy was associated with a 384% increase in euploid embryo production.
Conclusion: PRP demonstrated promising improvements in ovarian reserve and menstrual function compared with stem cell and secretome therapies. However, limited studies and substantial heterogeneity warrant larger, long-term randomized controlled trials to establish efficacy, optimal protocols, and safety.

Efek Terapi Platelet-Rich Plasma terhadap Cadangan Ovarium pada Wanita dengan Insufisiensi Ovarium Prematur

Abstrak
Pendahuluan: Insufisiensi Ovarium Prematur (IOP) ditandai hilangnya fungsi ovarium sebelum usia 40 tahun, dengan peningkatan gonadotropin, penurunan AMH, dan keterbatasan pilihan terapi. Kehamilan spontan hanya terjadi pada 5 – 10% kasus. Tinjauan sistematis ini mengevaluasi pengaruh terapi platelet-rich plasma (PRP), sekretom, dan sel punca terhadap pemulihan cadangan ovarium.
Metode: Mengikuti pedoman PRISMA 2020, pencarian dilakukan pada PubMed, Cochrane, dan MEDLINE untuk penelitian tahun 2020 – 2025. Studi klinis prospektif dan retrospektif pada manusia dengan IOP yang mendapat PRP, sekretom, atau sel punca disertakan. Kualitas metodologis dinilai menggunakan JBI Critical Appraisal Checklists.
Hasil: Lima penelitian melibatkan 211 partisipan. PRP menunjukkan tingkat keberhasilan 100%, dengan peningkatan jumlah folikel antral 75 – 176%, AMH 47 – 369%, dan penurunan FSH 16–62%. Menstruasi kembali pada 60% pasien. Sel punca menunjukkan keberhasilan keseluruhan 50%, sedangkan sekretom meningkatkan produksi embrio euploid sebesar 384%.
Kesimpulan: PRP menunjukkan hasil paling konsisten dan menjanjikan dalam pemulihan cadangan ovarium dan fungsi menstruasi dibandingkan sel punca dan sekretom. Namun, keterbatasan jumlah studi dan heterogenitas penelitian memerlukan uji klinis terkontrol acak yang lebih besar dan jangka panjang untuk memastikan efikasi, protokol optimal, dan keamanan.


Keywords


Platelet-rich plasma; stem cells; secretome, ovarian reserve; premature ovarian insufficiency; systematic review, fertility

Full Text:

PDF

References


Banu J, Jahan N, Anwary SA, et al. Effects of autologous stem cell therapy for fertility enhancement among women with premature ovarian insufficiency. Int J Reprod Contracept Obstet Gynecol. 2023;12(2):310-316. doi:10.18203/2320-1770.ijrcog20230114.

Eliás M, Kónya M, Kekk Z, et al. Platelet-rich plasma (PRP) treatment of the ovaries significantly improves fertility parameters and reproductive outcomes in diminished ovarian reserve patients: a systematic review and meta-analysis. J Ovarian Res. 2024;17:104. doi:10.1186/s13048-024-01423-2.

Cui X, Jing X. Stem cell-based therapeutic potential in female ovarian aging and infertility. J Ovarian Res. 2024;17:171. doi:10.1186/s13048-024-01492-3.

Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. Published 2021 Mar 29. doi:10.1136/bmj.n160.

Potiris A, Stavros S, Voros C, et al. Intraovarian Platelet-Rich Plasma Administration for Anovulatory Infertility: Preliminary Findings of a Prospective Cohort Study. J Clin Med. 2024;13(17):5292. Published 2024 Sep 6. doi:10.3390/jcm13175292.

Merhi Z, Seckin S, Mouanness M. Intraovarian platelet-rich plasma administration could improve blastocyst euploidy rates in women undergoing in vitro fertilization. Clin Exp Reprod Med. 2022;49(3):210-214. doi:10.5653/cerm.2021.05057.

Petryk N, Petryk M. Ovarian Rejuvenation Through Platelet-Rich Autologous Plasma (PRP)-a Chance to Have a Baby Without Donor Eggs, Improving the Life Quality of Women Suffering from Early Menopause Without Synthetic Hormonal Treatment. Reprod Sci. 2020;27(11):1975-1982. doi:10.1007/s43032-020-00266-8.

Sfakianoudis K, Simopoulou M, Grigoriadis S, et al. Reactivating Ovarian Function through Autologous Platelet-Rich Plasma Intraovarian Infusion: Pilot Data on Premature Ovarian Insufficiency, Perimenopausal, Menopausal, and Poor Responder Women. J Clin Med. 2020;9(6):1809. doi:10.3390/jcm9061809.

Mashayekhi M, Mirzadeh E, Chekini Z, et al. Evaluation of safety, feasibility and efficacy of intra-ovarian transplantation of autologous adipose derived mesenchymal stromal cells in idiopathic premature ovarian failure patients: non-randomized clinical trial. J Ovarian Res. 2021;14:5. doi:10.1186/s13048-020-00743-3.

Fakhrizal E, Simanjuntak AM, Hutapea A. Current evidence of platelet-rich blood plasma for pelvic organ prolapse: a review. Obgynia. 2023;6(3):339-343. doi:10.24198/obgynia.v6i3.530.

Shrivastava J, More A, Shrivastava V, Choudhary N, Shrivastava D. Enhancement of Ovarian Reserve and Oocyte Quality After Platelet-Rich Plasma Instillation in a Woman With Diminished Anti-Müllerian Hormone. Cureus. 2024;16(2):e53474. Published 2024 Feb 2. doi:10.7759/cureus.53474.

Sills ES. Ovarian recovery via autologous platelet-rich plasma: New benchmarks for condensed cytokine applications to reverse reproductive aging. Aging Med (Milton). 2022;5(1):63-67. Published 2022 Feb 5. doi:10.1002/agm2.12196.

Igboeli P, El Andaloussi A, Sheikh U, et al. Intraovarian injection of autologous human mesenchymal stem cells increases estrogen production and reduces menopausal symptoms in women with premature ovarian failure: two case reports and a review of the literature. J Med Case Rep. 2020;14:108. doi:10.1186/s13256-020-02426-5.

Cakiroglu Y, Saltik A, Yuceturk A, et al. Effects of intraovarian injection of autologous platelet rich plasma on ovarian reserve and IVF outcome parameters in women with primary ovarian insufficiency. Aging (Albany NY). 2020;12(11):10211-10222. doi:10.18632/aging.103403.

Herraiz S, Ruiz P, Garrido N, et al. Intraovarian injection of plasma rich in growth factors improves ovarian reserve and reproductive outcomes in women with diminished ovarian reserve. Hum Reprod. 2022;37(Suppl_1):deac104.058. doi:10.1093/humrep/deac104.058.

Singh N, Patel G, Dogra Y, Mohanty S, Seth T. Comparison of intra-ovarian platelet rich plasma versus autologous bone marrow derived stem cell instillation in women with diminished ovarian reserve for ovarian rejuvenation. Hum Reprod. 2022;37(Suppl_1):deac107.731. doi:10.1093/humrep/deac107.731.

Mi X, Jiao W, Yang Y, Qin Y, Chen ZJ, Zhao S. HGF secreted by mesenchymal stromal cells promotes primordial follicle activation by increasing the activity of the PI3K-AKT signaling pathway. Stem Cell Rev Rep. 2022;18:1834-1850. doi:10.1007/s12015-022-10335-x.




DOI: http://dx.doi.org/10.24198/obgynia.v9i3.1101

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.


     
  

Creative Commons License
Indonesian Journal of Obstetrics & Gynecology Science is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. 
  Web Analytics
  View My Stat